Neuroprotection for Parkinson's disease

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Koller, William C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DOPAMINE; LEVODOPA; SELEGILINE;

CONFERENCE PAPER; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DYSKINESIA; HUMAN; MENTAL DETERIORATION; MOTOR DYSFUNCTION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031719124     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440723     Document Type: Conference Paper

References (28)

1. Shoulson I. Protective therapy for Parkinson's disease. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1992:301-309
2. Marsden CD, Parkes JN. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1992;1:345-349
3. Shoulson I. Protective therapies for Parkinson's disease. In: Koller WC, Paulson GW, eds. Therapy of Parkinson's disease. New York: Marcel Dekker, 1990:352-368
4. Shults CW. Neurotrophic factors. In: Watts RL, Koller WC, eds. Movement disorders, neurologic principles and practice. New York: McGraw-Hill, 1997:117-123
5. Lindvall O, Barkland EO, Farle L, et al. Transplantation in Parkinson's disease. Two cases of adrenal medullary grafts to the putamen. Ann Neurol 1987;22:457-468
6. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation as a treatment for Parkinson's disease. Ann Neurol 1995;38:379-388
7. Birkmayer W, Knoff J, Riederer P, et al. Improvement of life expectancy due to L-deprenyl addition to madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 1985; 64:113-127
8. Knoll J. Extension of life span of rats by long term (-)deprenyl treatment. Mt Sinai J Med 1988;55:67-74
9. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;129:547-578
10. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984; 225:1480-1482
11. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37
12. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) in the natural history of Parkinson's disease. Science 1989;245: 519-522
13. Parkinsons Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46: 1052-1060
14. Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371
15. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanism? Neurology 1991;42(Suppl 6):13-26
16. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36
17. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777
18. Findley LJ. Selective monoamine oxidase B inhibitor (deprenyl) in Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. New York: Marcel Dekker, 1990:345-356
19. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-677
20. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenyl-pyridinium ion. J Neurochcm 1985;45:1951-1953
21. Ansari KS, Yu PH, Kruck TPA, Tatton WG. Rescue of axotomized immature rat facial motor neurons by R(!)-L-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053
22. Mytilineou C, Radcliffe P, Olanow CW. L-(-)-desmethylselegiline, a metabolite of L-(-)-selegiline, protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 1997;68:434-436
23. Leber P. Slowing the progression of Alzheimer's disease. Methodologic issues in Alzheimer's disease and associated disorders. Alzheimer Dis Assoc Disord 1997;11:510-521
24. 18F-dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591
25. Brooks D. Neuroimaging of movement disorders. In: Watts RL, Koller WC, eds. Movement disorders: neurologic principles and practice. New York: McGraw-Hill, 1997:31-48
26. Lee CS, Schulzer M, Mak E, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994;117: 501-507
27. Koller WC, Langston JW. Preclinical detection of Parkinson's disease. Neurology 1991;41(Suppl 2):1-94
28. Koller WC, Montgomery CM. Issues in the early diagnosis of Parkinson's disease. Neurology 1997;49(Suppl 1):S10-25